inc
datatim may updat industri model cloud wireless
inxn follow-up downgrad perform base
inc
break maintain perform
overreact grand scheme thing reiter outperform
color fundament focu call
updat dose underway volunt studi
brace turbul zynteglo trailblaz flight
doubl shot clinic data come
updat probe broader potenti nu platform
expect opregen dose reacceler restructur
ration prioriti
analyst certif import disclosur see
outreach growth drive confid estim
updat show program track data
updat show develop track
launch track maintain outperform
review cohort data eha phase ii initi
weak enterpris result manag transit back
result modest management believ dotdash vimeo
advertis local busi remain elus
strong us aarsd highlight solid fundament off-set recent
next takeaway survey result
strong growth difficult comparison off-set moder
lot move piec
eye margin profit tough near-term
rais confid
model updat earn call highlight crzo
short interest updat decreas industri back half
solid sign progress remain sidelin
mix result maintain op pt
wprt solid result across busi
better gross collect higher expens valuat allow
datatim may updat industri model cloud wireless also downgrad
inxn stock seen strong stock perform reach price target
cloud
inxn follow-up downgrad perform base valuat
downgrad inxn perform remov pt base valuat inxn nearli decemb low
within previou pt stock trade ebitda all-tim high see chart insid believ fundament
demand remain strong see momentum build across europ cloud provid revenu mix expand
footprint expect cloud activ attract enterpris want connect directli public cloud provid part hybrid multi-
cloud strategi would also like see better arpu growth come build slow risk includ high leverag neg
euro/brexit exposur
report apr result thursday see sales/ep line consensu modest neg bia street
juli expect dc remain sluggish near term hyperscal digest capac reflect recent peer commentari
expect dc spend pick consist asia channel check late-march check also reveal gpu channel
inventori back normal level set stage growth core game segment like strategic/accret
mlnx acquisit offer secular growth/gm expans rariti large-cap semi name maintain outperform
inc
break maintain perform
sinc announc strateg altern late-decemb under-perform declin vs ps result
believ market zero expect sold highlight valuat convers investor stock limit
downsid risk still screen attract unlock reward requir compstore turn stay posit improv net unit growth
refranchis final complet accret buy-back announc market cap expect unfold remain
public reiter target
overreact grand scheme thing reiter outperform
report adjust ep line estim slightli consensu adjust ep rose y/
compar consist compani long-term growth guidanc indic initi report april
consensu view high like disappoint sinc consensu come
closer estim would character result weak stock larg line expect view
sell-off overreact due misunderstand stori recommend investor take advantag weak ride
long-term growth stori
color fundament focu call
updat dose underway volunt studi
thursday alpin immun report earn review recent progress mark import transit clinic stage healthi
volunt hv dose compani dual antagonist phase trial first-in-class
molecul leverag alpin variant ig domain vigd scaffold target multipl immun pathway simultan proven safe hv
believ could evalu rang autoimmun disord start graft-versus-host diseas gvhd separ
alpin advanc ind could initi trial earli estim alpin cash runway extend late
potenti allow compani gener convinc proof-of-concept lead program reiter outperform pt
brace turbul zynteglo trailblaz flight
thursday bluebird bio host analyst day new york focus launch plan zynteglo transfusion-depend -thalassemia
tdt announc sever new early-stag addit pipelin anticip zynteglo could approv europ
initi commerci germani manag remain commit value-bas payment model vbpm allow zynteglo cost
amort yearli five year given potenti impact vbpm revenu recognit limit number plan initi
treatment center adjust near-term sale ramp believ bluebird nest assembl talent tool resourc
long-term success remain sidelin anticip bumpi zynteglo launch reiter perform
doubl shot clinic data come
report earn review recent progress anticip two critic near-term catalyst compani
result two on-going phase studi symptomat patient expect data may provid first real opportun gaug
metabol capac possibl answer question whether either product capabl make
meaning dent accumul toxic metabolit result announc via press releas confer call manag
could guid next step program current focus reformul product dri oral avail powder see
compat commerci ind oncology-focus remain track reiter outperform pt
updat probe broader potenti nu platform technolog
thursday volitionrx report result provid busi updat compani report steadi progress transit research-
grade nu assay commercial-grad diagnost product manag re-affirmed plan final first colorect cancer
diagnost panel perquisit valid studi final panel like add addit nu qs panel
previous show encourag perform cohort next month expect see multipl readout
trial product-grad diagnost develop varieti cancer includ result taiwanes lung cancer
cohort texas-bas subsidiari volit plan pursu commerci nu q-base diagnost veterinari medicin
expect opregen dose reacceler restructur ration prioriti
outperform rate base primarili two assumpt new manag would bring need priorit spend
result longer cash runway investor expect opregen dri offer attract applic compani
cell therapi divis financi result confer call disclos import step occur advanc
part thesi specif disclos plan termin employe recent acquir unit transfer respons
legaci employe follow transfer manufactur in-hous facil addit compani plan restart enrol
cohort opregen phase iia studi updat data expect meet octob
net loss came vs estim meaning data updat intermitt dose regimen differenti inhibitor
follicular lymphoma present meet abstract access start durabl
respons less-frequ dose well comparison tazemetostat inhibitor nda recent submit see share
inexpens rel commerci potenti earli data support reiter outperform rate
net loss came vs estim initi market approv luspatercept treat anemia low-risk md
transfusion-depend -thalassemia anticip us eu eventu label expans md non-tf-dep
-thal see aggreg sale opportun partner celg favor toward myelofibrosi data view
like posit stock catalyst part top-lin data ph wholly-own fshd cmt anticip
respect see sotatercept ph pulsar data pah reiter outperform pt
outreach growth drive confid estim growth
report revenu ahead expect vs importantli outreach pool grew may
decemb quarter expect reach goal well ahead schedul like geograph
expans state introduct ontrak program like drive opportun grow outreach pool substanti
increas outreach pool drive estim higher convert outreach pool enrol member come quarter
see upsid current estim outreach pool convert increas estim increas
target remain outperform
updat show program track data
provid updat financi result busi highlight net loss slightli better estim
result cash ep estim net loss guidanc includ share-
base comp estim annual cash burn next year would provid sever year runway
encourag progress prasinezumab parkinson diseas attr amyloidosi data
updat cohort total initi cell line develop preclin tau antibodi program partner celg
vital data recent report updat model actual guidanc
updat show develop track
report ep line estim cash balanc encourag progress
initi trial resmetirom nash patient follow posit result nash resolut biopsi safety/
toler addit data analys present easl support idea hepat fat reduct critic compon nash
resolut plan dyslipidemia studi initi view recent regener result posit
sinc potenti complementari profil focus nash resolut via hepat fat remov could complementari
oca work downstream fibrosi updat model actual detail insid
follow result updat model reflect quarterli financi price target remain unchang
launch track maintain outperform
report result provid busi updat note invelti launch progress ahead expect
revenu vs estim manag indic commerci live medicar live unrestrict
access medicar part contract negoti on-going broader coverag decis like earli expect invelti uptak
continu strong throughout year revenu reach higher prior estim continu
view strong launch stori note likelihood approv delay cautious optimist result
follow-on trial could support approv ultim
review cohort data eha phase ii initi forese
sunesi snss report earn gave corpor updat last month snss complet bid cohort
vecabrutinib safeti efficaci pk/pd data present european hematolog associ eha congress
abstract avail et snss current escal bid cohort snss also
present preliminari safeti data eha expect snss finish phase portion dose escal potenti enter phase
dose expans updat model stay bullish name
report adj -ep top opco/street consensu adj result exclud afam/
acquisit cost site closures/relocations/consolid impair charg beat vs model larg
driven tax rate cost control off-set soft top line partial due site closur meanwhil afam continu perform well
synergi still expect ramp quarter run rate year-end due tax rate adjust cost
control rais ep guidanc vs follow quarter tweak ep
though remain conserv earn outlook due reimburs uncertainti pdgm
top stori last week group earn conclud three post-acut stockslhcg ensgal report beat
rais annual outlook meanwhil also announc plan spin home health hospic
alf busi new compani call move would creat nimbler home-bas busi take better advantag
attract acquisit market mention strong multipl space
weak enterpris result manag transit back squar one
symc report result line consensu estim vs in-lin ep weak enterpris divis
result vs estim coupl lower guidanc disappoint light appear encourag sign
progress last quarter addit ceo greg clark depart symc replac interim board member richard hill
former novellu ceo current chairman marvel cfo nick noviello announc transit last quarter replac
vincent pilett logitech former cfo updat provid on-going sec investig wherea past three year
yield strateg chang hope back squar one perform
result modest management believ dotdash vimeo underappreci
rais target better outlook maintain outperform rate even share
overvalu reflect holdco discount share remain under-valued base target valu angi ebitda net
cash conserv valuat vimeo advertis meanwhil believ would gener addit cash
ad debt angi ahead spin-off within vimeo purchas magisto video edit compani add
sub dotdash continu show traction top advertis tinder sub track increas management focus upsid
india asia includ china
on-line advertis meet offlin growth sell advertis local busi remain elus
maintain perform rate revenu ebitda modestli exceed depress estim ebitda guidanc
street expect revenu y/i street paa modestli sequenti rev/paa street estim
ebitda estim ebitda guidanc expect cost-sav initi implement target
annual bolster ebitda growth initi enough off-set lost revenu reserv waitlist local
could seen potenti acquisit target maintain perform rate
strong us aarsd highlight solid fundament off-set recent traffic concern
report solid increas fy revenu guidanc acceler us aarsd y/i vs expand
intern footprint expect push-back us traffic deceler difficult-comp larg base howev maintain
domest traffic edg price strength impli solid fundament headway better optim exist user increas
connect capit one agreement like provid higher intent shopper without impact dealer lend econom see lender
onboard leverag site traffic gener record organ dealer ad attribut introduct brand
advertis select market maintain outperform traffic advantag proprietari valuat technolog gain increment share
dealer budget lead potenti increas estim
analyt collabor infrastructur softwar
next takeaway survey result
come away nutanix next confer increas confid demand compani core technolog solut clear
leadership valid ahv valu increment stronger spend expect long-term multi-cloud vision howev also
clear take time establish compani newer product saa servic convers show good awar
still mute interest/ne emphas high execut bar need balanc aggress product expans maintain
nutanix establish product redeploy sale personnel ramp new hire believ nutanix work issu
time continu wait sign execut becom construct maintain perform
tsmc roll process say report digitim
cpu ship june product launch digitim
target nm ee time
strong growth difficult comparison off-set moder beat-and-rais magnitud fundament remain
trade desk mark strong result better outlook off-set effect difficult y/i growth comparison
sign moder beat-and-rais magnitud investor like hope upsid quarter busi result
increas confid abil gain futur share digit advertis deliv faster growth higher margin versu
lead softwar supplier make success invest technolog support long-term growth bottom line believ
combin higher growth margin versu lead softwar vendor percept aggress new
modern platform technolog competit allow sustain premium valuat versu softwar industri reiter
emerg technolog servic
lot move piec
typic axon earn alway surpris good bad two constant axon steadfast belief put
agenc first tie focu drive long-term opportun focus hinder near term one focu
long-term growth expens near term may start hurt medium term worri axon would ramp spend
support myriad project primarili axon record remain case think increas likelihood miss oper
margin target base model axon like miss ebitda guidanc unless achiev guid revenu growth
emerg technolog servic
report result adj ebitda better estim identiv saw strong continu
margin expans consecut quarter posit adj ebitda despit march season low quarter compani
work govern shutdown also quarter compani award multipl multi-quart contract initi
thesi identiv grow well industri also get leverag across segment platform shift toward stronger
custom engag softwar centric access control quarter first mani reiter outperform
emerg technolog servic
eye margin profit tough near-term backdrop
report revenue/ep compar street top line slightli
recent reduc guidanc march believ tough handset market temporari vacuum senior manag
continu neg impact near-term outlook believ iot initi also see headwind next
month base recent channel check brighter side particip meaning ramp chines capac
compani also usb-c win top handset oem manag laser focus margin improv profit
could mean product-level restructur given on-going execut search weak handset market iot product headwind
emerg technolog servic
rais confid
report revenues/non-gaap ep better street strong
product traction effect channel manag improv market led strong result confid new product line-up
fall multipl posit consum retail trend manag rais annual sale ebitda guidanc gopro achiev
impress turnaround sinc last year manag demonstr solid execut abil adapt new market trend consum
demand manag also believ new entrant action camera market unlik gain meaning global share believ
gopro find new room grow servic adjac product despit domin share matur market reiter outperform
share remain sinc report close adj ep our/consensu
lower anticip infrastructur volum influenc sever weather resi weak aurora tragedi given factor
surpris noisi quarter recogn trade volatil around earn surpris howev
share significantli recov given solid fundament outlook msd core growth improv oper efficiency/
leverag result dd earn trajectori remain intact follow temporari headwind setup mind believ current
valuat ev/ebitda prove attract entri point small-cap investor
model updat earn call highlight crzo
formal updat estim summar key takeaway earn call herein four perform-r compani report earlier
week alway pleas reach updat work model
short interest updat decreas industri back half april
close thursday short interest data secur sever major exchang releas april note
decreas aggreg short interest compani coverag decreas across broader univers ps track
second half april summar data herein short interest chang coverag univers full report date
short interest chang broad univers page graphic repres chang short interest coverag compani
pp data report twice month typic delay
sustain growth resourc optim
solid sign progress remain sidelin
post top-line result ahead consensu modestli increas ebitda guidanc note strength intern
busi compani continu make progress evolv product portfolio start ship a-seri panel reach volum
product maxeon cell also post solid growth book energi storag solut believ compani
make progress toward target model articul analyst day look ebitda margin continu cautiou
compani cash posit given oper loss reduct cash exit exit look
compani begin gener consist posit get construct
sustain growth resourc optim
mix result maintain op pt
post deploy modestli ahead expect cost per watt come low end guidanc encourag
see compani return cost reduct trajectori cost guidanc come lower sequenti midpoint see
execut well evolv channel serv custom divers way especi energi storag cost come lower consum
interest increas encourag see expand channel partner part effort unlev npv per watt dip
may disappoint investor expect compani see metric rebound remain
construct reiter
sustain growth resourc optim
wprt solid result across busi
wprt post strong result maintain guidanc compani indic hpdi strength driver revenu growth
strong contribut cwi encourag see gm hold earli hpdi contribut continu see modest
ramp exist hpdi custom expect aggress volum ramp weichi potenti start continu
believ wprt light-duti solut well posit deliv upsid estim auto oem work reach emiss target
decreas primarili increas receiv expect compani activ engag improv dso remain construct
wprt given ip posit grow opportun set low-emiss offer
better gross collect higher expens valuat allow
report ep vs our/consensu includ one-tim item profit remain
pressur yoy measur ebit/invest capit said america continu grow faster segment higher ppm
total book continu edg toward balanc suppli continu increas anticip price becom increment favor
total gross collect vs revenu recognit lower expect net/net within
incom financ receiv expens higher valuat allow push core ep expect adjust
one-tim item continu wait stabil ebit/invest capit thu remain sidelin
june summit emerg biotechnolog montauk ny
